vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and PLAYSTUDIOS, Inc. (MYPS). Click either name above to swap in a different company.
PLAYSTUDIOS, Inc. is the larger business by last-quarter revenue ($55.4M vs $47.7M, roughly 1.2× IRONWOOD PHARMACEUTICALS INC). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -24.7%, a 19.9% gap on every dollar of revenue. On growth, PLAYSTUDIOS, Inc. posted the faster year-over-year revenue change (-18.3% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $3.6M). Over the past eight quarters, PLAYSTUDIOS, Inc.'s revenue compounded faster (-15.6% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
IRWD vs MYPS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $55.4M |
| Net Profit | $-2.3M | $-13.7M |
| Gross Margin | — | — |
| Operating Margin | 14.3% | -17.7% |
| Net Margin | -4.8% | -24.7% |
| Revenue YoY | -47.3% | -18.3% |
| Net Profit YoY | -200.9% | 38.9% |
| EPS (diluted) | $0.01 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | $55.4M | ||
| Q3 25 | $122.1M | $57.6M | ||
| Q2 25 | $85.2M | $59.3M | ||
| Q1 25 | $41.1M | $62.7M | ||
| Q4 24 | $90.5M | $67.8M | ||
| Q3 24 | $91.6M | $71.2M | ||
| Q2 24 | $94.4M | $72.6M | ||
| Q1 24 | $74.9M | $77.8M |
| Q4 25 | $-2.3M | $-13.7M | ||
| Q3 25 | $40.1M | $-9.1M | ||
| Q2 25 | $23.6M | $-2.9M | ||
| Q1 25 | $-37.4M | $-2.9M | ||
| Q4 24 | $2.3M | $-22.4M | ||
| Q3 24 | $3.6M | $-3.1M | ||
| Q2 24 | $-860.0K | $-2.6M | ||
| Q1 24 | $-4.2M | $-567.0K |
| Q4 25 | 14.3% | -17.7% | ||
| Q3 25 | 61.8% | -13.6% | ||
| Q2 25 | 53.2% | -5.9% | ||
| Q1 25 | -70.7% | -4.4% | ||
| Q4 24 | 34.8% | -33.1% | ||
| Q3 24 | 28.0% | -6.7% | ||
| Q2 24 | 26.5% | -5.5% | ||
| Q1 24 | 14.7% | -2.2% |
| Q4 25 | -4.8% | -24.7% | ||
| Q3 25 | 32.8% | -15.8% | ||
| Q2 25 | 27.7% | -5.0% | ||
| Q1 25 | -90.9% | -4.6% | ||
| Q4 24 | 2.5% | -33.1% | ||
| Q3 24 | 4.0% | -4.3% | ||
| Q2 24 | -0.9% | -3.6% | ||
| Q1 24 | -5.6% | -0.7% |
| Q4 25 | $0.01 | $-0.12 | ||
| Q3 25 | $0.23 | $-0.07 | ||
| Q2 25 | $0.14 | $-0.02 | ||
| Q1 25 | $-0.23 | $-0.02 | ||
| Q4 24 | $0.03 | $-0.18 | ||
| Q3 24 | $0.02 | $-0.02 | ||
| Q2 24 | $-0.01 | $-0.02 | ||
| Q1 24 | $-0.03 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $104.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-261.8M | $227.9M |
| Total Assets | $396.9M | $290.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | $104.9M | ||
| Q3 25 | $140.4M | $106.3M | ||
| Q2 25 | $92.9M | $112.9M | ||
| Q1 25 | $108.5M | $107.1M | ||
| Q4 24 | $88.6M | $109.2M | ||
| Q3 24 | $88.2M | $105.2M | ||
| Q2 24 | $105.5M | $106.3M | ||
| Q1 24 | $121.5M | $127.0M |
| Q4 25 | — | — | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $398.3M | — |
| Q4 25 | $-261.8M | $227.9M | ||
| Q3 25 | $-264.2M | $238.9M | ||
| Q2 25 | $-308.2M | $245.3M | ||
| Q1 25 | $-334.1M | $244.1M | ||
| Q4 24 | $-301.3M | $244.7M | ||
| Q3 24 | $-311.3M | $265.2M | ||
| Q2 24 | $-321.7M | $263.6M | ||
| Q1 24 | $-330.5M | $288.4M |
| Q4 25 | $396.9M | $290.6M | ||
| Q3 25 | $396.1M | $299.2M | ||
| Q2 25 | $342.9M | $316.2M | ||
| Q1 25 | $327.2M | $313.8M | ||
| Q4 24 | $350.9M | $323.0M | ||
| Q3 24 | $389.5M | $330.6M | ||
| Q2 24 | $395.6M | $333.4M | ||
| Q1 24 | $438.8M | $357.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $3.7M |
| Free Cash FlowOCF − Capex | $74.6M | $3.6M |
| FCF MarginFCF / Revenue | 156.3% | 6.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | $25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $3.7M | ||
| Q3 25 | $47.6M | $5.7M | ||
| Q2 25 | $-15.1M | $13.6M | ||
| Q1 25 | $20.0M | $3.3M | ||
| Q4 24 | $15.2M | $11.6M | ||
| Q3 24 | $9.9M | $14.6M | ||
| Q2 24 | $33.5M | $14.5M | ||
| Q1 24 | $45.0M | $5.0M |
| Q4 25 | $74.6M | $3.6M | ||
| Q3 25 | $47.6M | $5.4M | ||
| Q2 25 | $-15.1M | $13.2M | ||
| Q1 25 | $19.9M | $3.2M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | $9.9M | $13.9M | ||
| Q2 24 | $33.4M | $12.8M | ||
| Q1 24 | $44.9M | $3.6M |
| Q4 25 | 156.3% | 6.5% | ||
| Q3 25 | 39.0% | 9.3% | ||
| Q2 25 | -17.7% | 22.3% | ||
| Q1 25 | 48.4% | 5.1% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | 10.8% | 19.6% | ||
| Q2 24 | 35.4% | 17.6% | ||
| Q1 24 | 60.0% | 4.6% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.1% | 0.2% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.1% | 2.4% | ||
| Q1 24 | 0.1% | 1.9% |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | -0.64× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.74× | — | ||
| Q3 24 | 2.71× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
